Home Featured Page 11

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul...

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at...

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in...

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics

Exploring Psychedelist with Louis Dorian

Magic Mushrooms Meet Corporate Conspiracy: Steve Hely on Adult Swim’s Common...

Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose,...

Psychedelic Funding, Public Markets, and M&A in 2024

Neeka Levy and Zach Skiles – Healing Ukraine Trauma

1...101112...292 Page 11 of 292

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul...

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at...

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in...

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics

Exploring Psychedelist with Louis Dorian

Magic Mushrooms Meet Corporate Conspiracy: Steve Hely on Adult Swim’s Common...

Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose,...

Psychedelic Funding, Public Markets, and M&A in 2024

Neeka Levy and Zach Skiles – Healing Ukraine Trauma

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY